The Breast Cancer Research Program Reopened Two Mechanisms It Already Closed in July. The Second Window Spends Almost Exactly What Was Left of the $145 Million.
September 6, 2026 · 7 min read
Granted Research Team · Editorial policy
On September 3, 2026, the Congressionally Directed Medical Research Programs posted two funding opportunities that most breast cancer researchers had written off four months ago.
HT942526BCRPBTA122 — Breast Cancer Breakthrough Award Levels 1 and 2 — estimated funding $10,600,000, approximately 6 awards. And HT942526BCRPCREA2 — Breast Cancer Clinical Research Extension Award — estimated funding $8,400,000, approximately 1 award. Both close November 18, 2026, with a mandatory pre-application due to eBRAP by 5:00 p.m. ET on November 4, 2026.
Both mechanisms were already released this fiscal year. Both already closed. This is a second window in the same fiscal year, on the same appropriation, for the same two mechanisms — and CDMRP's own funding page labels them with a Roman numeral II.
That is rare enough to be worth understanding before you decide whether to write.
The full FY26 picture
The FY26 Breast Cancer Research Program received a $145 million congressional appropriation. Across its history the program has drawn $4.521 billion in appropriations from FY92 through FY25 — it is the oldest and one of the largest of the CDMRP portfolios.
Here is the entire FY26 slate as posted to Grants.gov, in two waves.
Wave one, posted May 4, 2026:
| Mechanism | Estimated funding | Awards | Closed |
|---|---|---|---|
| Breakthrough Award Levels 1 and 2 | $31,800,000 | 18 | July 8, 2026 |
| Clinical Research Extension Award | $15,400,000 | 2 | July 8, 2026 |
| Era of Hope Scholar Award | $4,900,000 | 1 | July 8, 2026 |
| Breakthrough Award Level 3 | $12,600,000 | 2 | September 30, 2026 |
| Breakthrough Award Level 4 | $21,000,000 | 1 | September 30, 2026 |
| Transformative Breast Cancer Consortium Award | $35,000,000 | 1 | September 30, 2026 |
Wave two, posted September 3, 2026:
| Mechanism | Estimated funding | Awards | Closes |
|---|---|---|---|
| Breakthrough Award Levels 1 and 2 (II) | $10,600,000 | 6 | November 18, 2026 |
| Clinical Research Extension Award (II) | $8,400,000 | 1 | November 18, 2026 |
Wave one totals $120.7 million. Wave two adds $19.0 million. The combined total is $139.7 million against a $145 million appropriation.
That is the number that resolves the ambiguity. If the second window were a re-pricing — CDMRP deciding the first round had been oversubscribed, or under-reviewed, and re-running it — you would expect the two Levels 1 and 2 announcements to overlap in scope and for the totals to exceed the appropriation. They do not. The second window consumes almost exactly the remaining unobligated balance of the FY26 appropriation, leaving roughly $5 million for program administration and the mechanisms not listed here.
Read plainly: this is not a do-over. It is a supplemental tranche, and the money is real.
The award economics did not change
Wave one Levels 1 and 2: $31.8 million across 18 awards is about $1.77 million per award. Wave two: $10.6 million across 6 awards is about $1.77 million per award.
Identical. CDMRP did not shrink the awards to stretch the money; it funded a smaller number of awards at the same size. If you were competitive on budget in July, you are competitive on budget in November, and you should not restructure your scope on the assumption that the second window rewards a leaner project.
The Clinical Research Extension Award moves slightly the other way. Wave one was $15.4 million for 2 awards — $7.7 million each. Wave two is $8.4 million for a single award. Whatever else is true, this is a one-award competition, and applicants should plan accordingly.
What the mechanisms fund
The Breakthrough Award supports research with high potential to lead to or make breakthroughs in breast cancer. Every application must address at least one of the program's FY26 overarching challenges or provide adequate justification for an exception. Those challenges are:
- Prevent breast cancer (primary prevention)
- Identify determinants of breast cancer initiation, risk, or susceptibility
- Distinguish deadly from non-deadly breast cancers
- Conquer the problems of overdiagnosis and overtreatment
- Identify what drives breast cancer growth and determine how to stop it
- Identify why some breast cancers become metastatic
- Determine the mechanisms of dormancy and prevent lethal recurrence
- Revolutionize treatment regimens to improve survival and effectiveness and reduce toxicity
- Eliminate mortality associated with metastatic breast cancer
The Breakthrough mechanism spans four funding levels; this announcement covers Levels 1 and 2 only. For the FY26 cycle, Level 1 has been offered at up to $750,000 total costs for a single principal investigator, or $1.25 million under the Partnering PI Option. Level 2 runs up to $1.65 million single-PI or $2.50 million with a partnering PI, and Level 2 includes a Population Science Studies option at up to $2.50 million single-PI or $3.35 million with a partnering PI. With compelling justification, population science studies may request higher funding and an additional year of performance. Confirm every cap against the program announcement PDF for this specific release — level structures are stable across CDMRP cycles but the caps are not something to take from a summary table, including this one.
The Clinical Research Extension Award is the more distinctive of the two. It supports research that extends the data collection, follow-up, and analysis of existing breast cancer clinical studies. The stated intent is to recover value from what the program calls knowledge lost — data that never materialized because a trial terminated early, because patient follow-up was too short, or because sample and data collection were suboptimal.
This is a mechanism for people sitting on a cohort that was never fully exploited. If you have a trial that closed early, a biorepository with consented specimens and no analysis funding, or a study whose survival curves were truncated by the end of a grant period, this is the announcement written for you. It is also a mechanism where the strongest applications are the ones that can name the specific clinical question the original study could not answer and show, concretely, that the extension closes it.
The requirements that eliminate people
The pre-application is mandatory and it comes first. The pre-application deadline is November 4, 2026 at 5:00 p.m. ET, submitted through eBRAP. The full application is due November 18, 2026 at 11:59 p.m. ET through Grants.gov. Two weeks separate them. Missing November 4 ends your FY26 participation regardless of how good the science is — CDMRP does not accept late pre-applications, and the full application cannot be submitted without one.
The Partnering PI Option has a trap. Under PPIO, only the Initiating PI submits the pre-application, but both PIs submit at the full application stage. The announcement is explicit that failure to submit all associated applications by the deadline may result in administrative withdrawal. Two institutions, two research administration offices, one deadline — and if the partnering institution's office treats November 18 as a soft target, both applications die. Confirm the partnering institution's internal deadline in writing this month, not in November.
The Clinical Research Extension Award requires two or more breast cancer consumer advocates on the research team. Not one. Not an advisory board that meets annually. Two or more, on the team. Consumer advocacy involvement is foundational to how CDMRP reviews — advocates sit on the peer and programmatic review panels — and a team assembled without them will read as unfamiliar with the program. Recruiting two advocates with the right disease experience and the availability to engage meaningfully is a multi-week task. Start it now.
Neither mechanism requires cost sharing. That is one fewer institutional negotiation.
The timing question nobody asks
Awards made from FY26 funds must be made no later than September 30, 2027, and the funds expire for use on September 30, 2032. Work backward: a November 18 submission goes through a two-tier review — scientific peer review followed by programmatic review by the Integration Panel — with negotiation and award in the spring or summer of 2027. That is a tight but entirely normal CDMRP cycle, and it is the practical reason the second window exists at all. Reopening in September is the last point in the fiscal year at which a full review cycle still fits inside the obligation deadline.
It also means the second window will almost certainly not be followed by a third.
Who should actually write
If you submitted to wave one and were not funded, wait for your summary statement before you decide. CDMRP feedback is substantive, and a resubmission that visibly answers the panel's critique is a different application than one that resubmits unchanged with a new date. If the critique was about scope or feasibility, six weeks is enough to fix it. If it was about the underlying premise, it is not.
If you did not submit to wave one, the honest question is why. If the answer is that the July deadline collided with something, this is a clean second chance at the same money for the same work. If the answer is that the science was not ready in May, ask whether it is ready now — six awards is a narrow gate, and the July applicants who resubmit will have panel feedback that you will not.
If you hold an under-analyzed breast cancer cohort, the Clinical Research Extension Award is a one-award competition and the least crowded thing on this list. It is also the one that requires the most assembly: two consumer advocates, documented access to the original study's data and specimens, and a defensible account of what was lost. Six weeks is enough for that only if you begin immediately.
For the wider CDMRP portfolio and how the Defense Health Program's medical research lines are structured, see our overview of the $1.27 billion CDMRP appropriation.
Verify all figures, caps, deadlines, and eligibility against the official program announcement on eBRAP and Grants.gov before applying. Pre-application deadline: November 4, 2026, 5:00 p.m. ET. Application deadline: November 18, 2026, 11:59 p.m. ET.